Oregon
State Facts
Deaths or 72.3% of total overdose deaths involved opioids in 2024.¹
Claims or 5.15% of all Medicare Part D claims were for opioids in 2022 – an average of 49 per prescriber.²
Opioid Prescriptions were written for every 100 persons in Oregon in 2023.³
Beneficiaries on Medicare Part D had Opioid Use Disorder in 2022.⁴
Opioid Settlement Funds
Oregon’s Opioid Settlement Prevention, Treatment, and Recovery (OSPTR) Board will allocate 21-22% to harm reduction and overdose prevention, primary prevention, treatment, and recovery. The remaining 3-6% is directed towards research and evaluation; leadership, planning, and coordination; emerging issues; and administrative costs and expenses.
Co-Sponsors (119th)
Sen. Jeff Merkley (D-OR)
Rep. Andrea Salinas (D-OR-6)
2025 Introduced Relevant Legislation
SB 598
This legislation requires that state Medicaid and commercial insurance plans use the same utilization review and cost-sharing requirements for opioid and nonopioid drugs when they are prescribed for the same treatment.
Introduced
01/10/2025Plan Impact
Medicaid & CommercialHB 3211
Requires the Oregon Health Authority to develop and make available a nonopioid directive form.
Signed into law May 27, 2025.
Introduced
01/13/2025Voices Letters
SB 598 Letter of Support
1. Centers for Disease Control and Prevention (2025). Provisional Drug Overdose Death Counts. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
2. Centers for Disease Control and Prevention (2024). Medicare Part D Opioid Prescribing Mapping Tool. https://cms-oeda.maps.arcgis.com/apps/MapSeries/index.html?appid=5390718d875d4c049b1ac5976a9ff083
3. Center for Disease Control and Prevention (2024). Opioid Dispensing Rate Maps. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/opioid-dispensing-rate-maps.html
4. Office of the Inspector General (2023). The Consistently Low Percentage of Medicare Enrollees Receiving Medication to Treat Their Opioid Use Disorder Remains a Concern. https://oig.hhs.gov/documents/evaluation/2722/OEI-02-23-00250-Complete%20Report.pdf



































































